Wang Zi-Xuan, Tan Lan, Yu Jin-Tai
Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.
Mol Neurobiol. 2015;51(3):1309-21. doi: 10.1007/s12035-014-8810-x. Epub 2014 Jul 23.
A large body of evidences indicates that axonal transport (AT) defects play an important role in the pathogenesis of Alzheimer' disease (AD). AT, a critical cellular process for the maintenance and function of a neuron, requires components of the cytoskeletons as "tracks", motor proteins and ATP as "driving force", adaptor proteins to ensure the specific connection of the transported cargoes and motor proteins as well as active regulation. In AD pathology, AD-linked pathologic factors respectively perturb the four basic components of AT through different signaling pathways to cause AT defects. Mitochondrial transport, which is different from other transport cargoes, is also impaired via special pathways in AD. In this paper, we review the inhibitory effects of those factors on AT and their possible pathways, indicating these factors act in overlapping, synergistic, and circulating ways. Given the contributions of AT defects to AD, recent therapeutic studies focus on microtubule-stabilizing (MT-stabilizing) agents and alteration in phosphotransferase activities, and we propose more therapeutic strategies targeting AT defects.
大量证据表明,轴突运输(AT)缺陷在阿尔茨海默病(AD)的发病机制中起重要作用。轴突运输是神经元维持和功能的关键细胞过程,需要细胞骨架成分作为“轨道”、驱动蛋白和ATP作为“驱动力”、衔接蛋白以确保运输货物与驱动蛋白的特异性连接以及积极的调控。在AD病理学中,与AD相关的病理因素分别通过不同的信号通路扰乱轴突运输的四个基本成分,导致轴突运输缺陷。与其他运输货物不同,线粒体运输在AD中也通过特殊途径受损。在本文中,我们综述了这些因素对轴突运输的抑制作用及其可能的途径,表明这些因素以重叠、协同和循环的方式起作用。鉴于轴突运输缺陷对AD的影响,最近的治疗研究集中在微管稳定剂和磷酸转移酶活性的改变上,并且我们提出了更多针对轴突运输缺陷的治疗策略。